Study of the opioid antagonist activity of a novel fluorinated diprenorphine derivative

BACKGROUND: The growing chemical diversity of abused opioids, coupled with the use of synthetic opioids as chemical warfare agents, has created a pressing global need for effective medical countermeasures against opioid toxicity. Rationally modifying the molecular scaffolds of compounds with established pharmacological activity is an effective approach to developing novel therapeutics. In particular, fluorinating such molecules can profoundly alter their pharmacokinetic and pharmacodynamic properties.

AIM: To discover fluorinated derivatives of diprenorphine that could serve as candidate antidotes for opioid poisoning.

METHODS: To analyze the effects of the fluorinated N-allyl-6-O-demethylated diprenorphine analogue – (5R,6R,7S,20R)-4,5-epoxy-3,6-dihydroxy-7-(1-hydroxy-1-methyl-2,2,2-trifluoroethyl)-17-(prop-2-en-1-yl)-6,14-ethanoisomorphinan, synthesized at the A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences – on pain thresholds in mice, a physiological pain model (the “Tail-flick” test) was used. Morphine served as a reference control to evaluate analgesic efficacy, while diprenorphine was used as a reference control to assess the antagonistic activity of the experimental compound against morphine-induced analgesia.

RESULTS: The experimental compound (0.1 – 10 mg/kg, sc) exhibited no intrinsic analgesic activity, whereas morphine elicited robust analgesic effects within the same dose range. Pretreatment with the experimental compound (0.1 – 10 mg/kg, sc; 30 min prior to morphine administration) abolished the analgesic effect of morphine (5 mg/kg, sc) at doses of 1 or 10 mg/kg; at the highest dose, this antagonistic effect persisted for at least 120 min. Diprenorphine, the prototype compound, exhibited statistically significant antagonistic activity at all tested doses (0.001 – 0.1 mg/kg, sc) during the entire assessment period (up to 120 min).

CONCLUSION: The properties of the new fluorinated diprenorphine derivative, which exhibits antagonist activity toward μ-opioid receptors, require further investigation to determine its potential use as an antidote for opioid poisoning.